Medicines for Specific Cancers (E through L)
Drugs Approved for Endometrial Cancer
Dostarlimab
Lenvatinib
Megestrol
Pembrolizumab
Drugs Approved for Esophageal Cancer
Docetaxel
Nivolumab
Pembrolizumab
Ramucirumab
Trastuzumab
Trifluridine and Tipiracil
Drugs Approved for Gastrointestinal Stromal Tumors
Avapritinib
Imatinib
Regorafenib
Ripretinib
Sunitinib
Drugs Approved for Gestational Trophoblastic Disease
Dactinomycin
Methotrexate
Vinblastine
Drugs Approved for Head and Neck Cancer
Bleomycin
Cetuximab
Docetaxel
Hydroxyurea
Methotrexate
Nivolumab
Pembrolizumab
Drugs Approved for Hodgkin’s Disease
Bleomycin
Brentuximab Vedotin
Carmustine
Chlorambucil
Cyclophosphamide
Dacarbazine
Dexamethasone
Doxorubicin
Lomustine
Mechlorethamine
Nivolumab
Pembrolizumab
Prednisone
Procarbazine
Vinblastine
Vincristine
Drugs Approved for Kaposi Sarcoma
Doxorubicin
Paclitaxel
Interferon
Paclitaxel
Vinblastine
Drugs Approved for Kidney (Renal Cell) Cancer
Aldesleukin
Avelumab
Axitinib
Bevacizumab
Cabozantinib
Everolimus
Ipilimumab
Lenvatinib
Mitomycin
Nivolumab
Pazopanib
Pembrolizumab
Sorafenib
Sunitinib
Temsirolimus
Tivozanib
Drugs Approved for Acute Myeloid leukemia (AML)
Asparaginase
Blinatumomab
Calaspargase Pegol-mknl
Clofarabine
Cyclophosphamide
Cytarabine
Dasatinib
Daunorubicin
Dexamethasone
Doxorubicin
Imatinib
Inotuzumab Ozogamicin
Mercaptopurine
Methotrexate
Nelarabine
Pegaspargase
Ponatinib
Prednisone
Tisagenlecleucel
Vincristine
Drugs Approved for Acute Lymphoblastic Leukemia (ALL)
Arsenic Trioxide
Cyclophosphamide
Cytarabine
Daunorubicin
Dexamethasone
Doxorubicin
Enasidenib
Gemtuzumab
Gilteritinib
Glasdegib
Idarubicin
Ivosidenib
Midostaurin
Mitoxantrone
Thioguanine
Venetoclax
Vincristine
Drugs Approved for Chronic Myeloid Leukemia (CML)
Bosutinib
Busulfan
Cyclophosphamide
Cytarabine
Dasatinib
Dexamethasone
Hydroxyurea
Imatinib
Nilotinib
Omacetaxine
Ponatinib
Drugs Approved for Chronic Lymphocytic Leukemia (CLL)
Acalabrutinib
Alemtuzumab
Bendamustine
Chlorambucil
Cyclophosphamide
Dexamethasone
Duvelisib
Fludarabine
Ibrutinib
Idelalisib
Obinutuzumab
Ofatumumab
Prednisone
Rituximab
Venetoclax
Drugs Approved for Hairy Cell Leukemia
Cladribine
Interferon
Moxetumomab
Drugs Approved for Mast Cell Leukemia
Midostaurin
Drugs Approved for Meningeal Leukemia
Cytarabine
Drugs Approved for Liver Cancer
Atezolizumab
Bevacizumab
Cabozantinib
Lenvatinib
Nivolumab
Pembrolizumab
Pemigatinib
Ramucirumab
Regorafenib
Sorafenib
Drugs Approved for Non-Small Cell Lung Cancer
Alectinib
Atezolizumab
Bevacizumab
Brigatinib
Capmatinib
Carboplatin
Ceritinib
Crizotinib
Dabrafenib
Dacomitinib
Docetaxel
Doxorubicin
Durvalumab
Entrectinib
Erlotinib
Everolimus
Gefitinib
Gemcitabine
Ipilimumab
Lorlatinib
Methotrexate
Necitumumab
Nivolumab
Osimertinib
Paclitaxel
Pembrolizumab
Pemetrexed
Pralsetinib
Ramucirumab
Selpercatinib
Tepotinib
Trametinib
Drugs Approved for Small Cell Lung Cancer
Atezolizumab
Doxorubicin
Durvalumab
Etoposide
Everolimus
Lurbinectedin
Methotrexate
Nivolumab
Pembrolizumab
Other Cancers
Medicines Approved for Specific Cancers (A-D)
Medicines Approved for Specific Cancers (M-Z)
Chemo agents for specific cancers in PDF format.